Scientists at HDT Bio Corp, Duke University School of Medicine, and Seattle Children’s Research Institute have taken another step toward successfully developing mRNA vaccines that could protect against mother-to-child transmission of pathogens. The team used a proprietary vaccine platform called LIONTM/repRNA to deliver self-amplifying replicon (repRNA) vaccines targeting Zika virus and HIV-1 in pregnant rabbits. The study’s results, published in Molecular Therapy, showed that the vaccines produced strong antibody responses that were passed on to the offspring in utero.
Search Antibodies Search Now Use our Antibody Search Tool to find the right antibody for your research. Filter
by Type, Application, Reactivity, Host, Clonality, Conjugate/Tag, and Isotype.
The researchers chose Zika virus and HIV-1 as model disease targets since they are significant causes of infections in newborns after mother-to-child transmission. Preventing such transmission is a major goal for reducing disease burden in newborns.
The study revealed that repRNA immunization at a relatively high dose was well tolerated and had no detrimental impact on litter size. The LIONTM/repRNA vaccines also triggered robust antigen-specific antibody responses in pregnant adult rabbits that were likely passively transferred to offspring in utero. The timing of maternal vaccination was critical for maximizing antibody transfer, and subsequent vaccination in newborns maintained elevated antibody levels compared to no vaccination.
The researchers used a matrixed study design to understand the effect of vaccination in kits on the presence of pre-existing maternal antibodies. Their findings showed that the timing of maternal vaccination is crucial for maximizing in utero antibody transfer, and subsequent vaccination in newborns maintained elevated antibody levels compared with no vaccination.
However, more research is needed to determine whether RNA-based maternal vaccines can offer protection against infection by mother-to-child transmission. The authors say further studies will be needed to test boosting intervals and the durability of antibody responses to maximize passive antibody transfer to newborns.
mRNA vaccines’ success in response to the COVID-19 pandemic spurred interest in developing additional vaccines targeting other infectious diseases. The team believes their findings can help support further development of the LIONTM/repRNA vaccine platform, which could help protect against mother-to-child transmission of pathogens in animals and humans.